Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
View:

• All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study

• All participants will be eighteen years old or older

• Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.

• Ability to understand and the willingness to sign a written informed consent document.

• Pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell)

• Women of childbearing potential must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry.

• A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

‣ Has not undergone a hysterectomy or bilateral oophorectomy; or

⁃ Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Locations
United States
New Mexico
University of New Mexico Cancer Center
RECRUITING
Albuquerque
Contact Information
Primary
Sarah Adams, MD
SAdams@salud.unm.edu
(505) 925-0461
Backup
Amy Overby
Aoverby1@salud.unm.edu
505-272-5557
Time Frame
Start Date: 2015-12-02
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: New Mexico Cancer Research Alliance

This content was sourced from clinicaltrials.gov